-

iXensor’s Eveline·Care Telehealth Empowering Fertility Services to Assist Patients’ Conceptions With At-Home Test Monitoring

PALO ALTO, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--iXensor, the pioneer of mobile health, launches its new Eveline·Care service, effectively turning the smartphone-based Eveline Ovulation Predictor Kit (OPK) into a telehealth-enabled fertility monitoring system. This telehealth service is anticipated by OB-GYN practitioners and highly appreciated by patients for comfortable at-home testing, especially amid the ongoing COVID-19 pandemic globally.

Helping couples to conceive all around the world

Aiming to help couples ease the stress of trying to conceive, iXensor develops Eveline, an AI-powered ovulation prediction kit based on its patented PixoTech® technology, transforming smartphones into at-home testing devices. Eveline leverages front cameras of smartphones to analyze luteinizing hormone (LH) test strips and inform current ovulation status with 99% accuracy. On top of that, the AI-powered Eveline App predicts up to 5 fertile days per menstruation cycle. Users are then conveniently reminded through personalized notifications, thus they never miss the peak time to get pregnant.

What does Eveline·Care offer?

Eveline·Care is a telehealth platform that enables fertility consultants to seamlessly access their patients' timely ovulation test data and recorded symptoms through a live dashboard presentation, including a hormone profile chart. Eveline users authorize participating fertility consultants to access their fertility data captured on the Eveline App. Such data includes their luteinizing hormone (LH) levels, basal body temperature (BBT), mood, diet, and daily symptoms. Eveline·Care allows physicians to monitor a patient's fertility condition in real-time remotely and provide comprehensive consultation.

"Eveline·Care gives patients a better understanding of their hormonal patterns and makes the communication with doctors more straightforward. The feedback we are getting from patients is very encouraging," said Mei-Chao Hsu, M.D., Director at Sumay's Medical Clinic.

How does Eveline·Care facilitate IUI?

Another use case of Eveline·Care lies in supporting Intrauterine Insemination (IUI) treatments. For a successful IUI procedure, the timing is crucial. Once the LH surge happens, the participating physician is automatically notified through Eveline·Care platform and can invite the patient back to the clinic in time for the IUI procedure. This solution increases the chance of a successful IUI treatment by reducing the risk scenario that the patient ovulates earlier than expected.

Attending doctor Yi-Pin Li commented on the service: "Eveline·Care platform empowers us to monitor IUI patients' hormonal levels frequently and remotely, so we can make sure they don't miss their critical timings in the IUI treatment. As a result, our patients feel confident knowing their doctors are always monitoring their status for IUI procedure and thereby ensuring a higher success rate."

About iXensor

iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, and cardiovascular diseases.

Contacts

Media
Spokesperson: Patrick Liao
Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-928-570-208

iXensor


Release Versions

Contacts

Media
Spokesperson: Patrick Liao
Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-928-570-208

Social Media Profiles
More News From iXensor

iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement

TAIPEI, Taiwan & OSAKA, Japan--(BUSINESS WIRE)--Rohto Pharmaceutical Co. announces strategic investment in iXensor and licenses PixoTech technology to co-develop new self-testing portfolios....

iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern

TAIPEI, Taiwan--(BUSINESS WIRE)--iXensor Co., Ltd. (6734.TWO) iXensor, the pioneer of mobile health, declares that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies. In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein o...

iXensor Levels Up PixoTest® COVID-19 Ag Test With the Launch of PixoHealth Data Management Platform as the Security Solution for the New Normalcy

TAIPEI, Taiwan--(BUSINESS WIRE)--iXensor Co., Ltd. (6734.TWO) iXensor launches the next generation of integrated COVID-19 screening solution, the PixoHealth Pass Admin App and Web Portal. The PixoHealth Pass Admin App is a virtual gatekeeper, which screens and verifies the COVID-19 related health conditions through a scan of QR code displayed by PixoHealth Pass App users. In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test resu...
Back to Newsroom